{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:18:11Z","timestamp":1794410291182,"version":"4.9.0"},"reference-count":119,"publisher":"Oxford University Press (OUP)","issue":"20","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Remarkable progress has been made in the pharmacological management of patients with cardiovascular disease, including the frequent use of antithrombotic agents. Nonetheless, bleeding complications remain frequent and potentially life-threatening. Therapeutic interventions relying on prompt antithrombotic drug reversal or removal have been developed to assist clinicians in treating patients with active bleeding or an imminent threat of major bleeding due to urgent surgery or invasive procedures. Early phase studies on these novel strategies have shown promising results using surrogate pharmacodynamic endpoints. However, the benefit of reversing\/removing antiplatelet or anticoagulant drugs should always be weighed against the possible prothrombotic effects associated with withdrawal of antithrombotic protection, bleeding, and surgical trauma. Understanding the ischemic-bleeding risk tradeoff of antithrombotic drug reversal and removal strategies in the context of urgent high-risk settings requires dedicated clinical investigations, but challenges in trial design remain, with relevant practical, financial, and ethical implications.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehad119","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T05:46:02Z","timestamp":1680155162000},"page":"1780-1794","source":"Crossref","is-referenced-by-count":33,"title":["Reversal and removal of oral antithrombotic drugs in patients with active or perceived imminent bleeding"],"prefix":"10.1093","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7755-4069","authenticated-orcid":false,"given":"Davide","family":"Cao","sequence":"first","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 , USA"},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele-Milan , Italy"},{"name":"Department of Cardiology, Humanitas Gavazzeni , Bergamo , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9092-4458","authenticated-orcid":false,"given":"Nicolas","family":"Amabile","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Mutualiste Montsouris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-2658","authenticated-orcid":false,"given":"Mauro","family":"Chiarito","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele-Milan , Italy"},{"name":"Department of Cardiology, IRCCS Humanitas Research Hospital , Rozzano-Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria T","family":"Lee","sequence":"additional","affiliation":[{"name":"PAVmed Inc. , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J","family":"Angiolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Florida College of Medicine , Jacksonville, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5156-7723","authenticated-orcid":false,"given":"Davide","family":"Capodanno","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Azienda Ospedaliero Universitaria Policlinico \u2018G. Rodolico-San Marco\u2019, University of Catania , Catania , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Heart, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Mack","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Baylor Scott and White Health , Plano, TX , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield , Sheffield , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schmoeckel","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Asklepios Klinik St. Georg , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymios N","family":"Deliargyris","sequence":"additional","affiliation":[{"name":"CytoSorbents Corporation , Princeton, NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Center for Interventional Cardiovascular Research and Clinical Trials, The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai , One Gustave L. Levy Place, Box 1030, New York, NY 10029-6574 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"2023052108544622400_ehad119-B1","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/CIRCRESAHA.118.313155","article-title":"Antithrombotic agents","volume":"124","author":"Chan","year":"2019","journal-title":"Circ Res"},{"key":"2023052108544622400_ehad119-B2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/eurheartj\/ehaa824","article-title":"Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey","volume":"42","author":"Cao","year":"2021","journal-title":"Eur Heart J"},{"key":"2023052108544622400_ehad119-B3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4244\/EIJ-D-20-01197","article-title":"Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis","volume":"17","author":"Piccolo","year":"2021","journal-title":"EuroIntervention"},{"key":"2023052108544622400_ehad119-B4","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1161\/CIRCULATIONAHA.110.963843","article-title":"Aspirin: a historical and contemporary therapeutic overview","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"2023052108544622400_ehad119-B5","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11606-020-05904-0","article-title":"Oral anticoagulant utilization in the United States and United Kingdom","volume":"35","author":"Colacci","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2023052108544622400_ehad119-B6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.21037\/atm.2017.06.65","article-title":"Direct oral anticoagulants: analysis of worldwide use and popularity using Google trends","volume":"5","author":"Lippi","year":"2017","journal-title":"Ann Transl Med"},{"key":"2023052108544622400_ehad119-B7","first-page":"804","article-title":"Trade-off of myocardial infarction vs. Bleeding types on mortality after acute coronary syndrome: lessons from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER) randomized trial","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"2023052108544622400_ehad119-B8","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11606-019-05391-y","article-title":"Emergency visits for oral anticoagulant bleeding","volume":"35","author":"Geller","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2023052108544622400_ehad119-B9","doi-asserted-by":"crossref","first-page":"e004517","DOI":"10.1161\/JAHA.116.004517","article-title":"Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life danish patients","volume":"6","author":"Lamberts","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2023052108544622400_ehad119-B10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"2023052108544622400_ehad119-B11","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"2023052108544622400_ehad119-B12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41569-021-00598-1","article-title":"Bleeding avoidance strategies in percutaneous coronary intervention","volume":"19","author":"Capodanno","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2023052108544622400_ehad119-B13","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.jacc.2021.07.048","article-title":"Intracranial hemorrhage during dual antiplatelet therapy: jACC review topic of the week","volume":"78","author":"Ha","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023052108544622400_ehad119-B14","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2015-01-622928","article-title":"Structural and functional characterization of a specific antidote for ticagrelor","volume":"125","author":"Buchanan","year":"2015","journal-title":"Blood"},{"key":"2023052108544622400_ehad119-B15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/jth.13680","article-title":"Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin","volume":"15","author":"Pehrsson","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B16","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1056\/NEJMoa1901778","article-title":"Antibody-based ticagrelor reversal agent in healthy volunteers","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B17","first-page":"oa2100047","article-title":"Bentracimab for ticagrelor reversal in patients undergoing urgent surgery","volume":"1","author":"Bhatt","year":"2021","journal-title":"NEJM Evid"},{"key":"2023052108544622400_ehad119-B18","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.3390\/jcm9072318","article-title":"Management of bleeding events associated with antiplatelet therapy: evidence, uncertainties and pitfalls","volume":"9","author":"Godier","year":"2020","journal-title":"J Clin Med"},{"key":"2023052108544622400_ehad119-B19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1538-7836.2006.02245.x","article-title":"Normalization of platelet reactivity in clopidogrel-treated subjects","volume":"5","author":"Vilahur","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B20","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/jth.12058","article-title":"Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation","volume":"11","author":"Zafar","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/bja\/aet339","article-title":"Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor","volume":"112","author":"Hansson","year":"2014","journal-title":"Br J Anaesth"},{"key":"2023052108544622400_ehad119-B22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1056\/NEJMc1409373","article-title":"Inefficacy of platelet transfusion to reverse ticagrelor","volume":"372","author":"Godier","year":"2015","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B23","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1111\/jth.13511","article-title":"Effects of autologous platelet transfusion on platelet inhibition in ticagrelor-treated and clopidogrel-treated subjects","volume":"14","author":"Teng","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3109\/09537104.2015.1035247","article-title":"Impact of non-inhibited platelet supplementation on platelet reactivity in patients treated with prasugrel or ticagrelor for an acute coronary syndrome: an ex vivo study","volume":"26","author":"Bonhomme","year":"2015","journal-title":"Platelets"},{"key":"2023052108544622400_ehad119-B25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/EJA.0000000000000348","article-title":"The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study","volume":"33","author":"Martin","year":"2016","journal-title":"Eur J Anaesthesiol"},{"key":"2023052108544622400_ehad119-B26","doi-asserted-by":"crossref","first-page":"e005120","DOI":"10.1161\/CIRCINTERVENTIONS.117.005120","article-title":"Impact of timing on the functional recovery achieved with platelet supplementation after treatment with ticagrelor","volume":"10","author":"Zafar","year":"2017","journal-title":"Circ Cardiovasc Interv"},{"key":"2023052108544622400_ehad119-B27","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jth.14014","article-title":"Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor","volume":"16","author":"Bertling","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3171\/2012.9.JNS112286","article-title":"Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage","volume":"118","author":"Li","year":"2013","journal-title":"J Neurosurg"},{"key":"2023052108544622400_ehad119-B29","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0140-6736(16)30392-0","article-title":"Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial","volume":"387","author":"Baharoglu","year":"2016","journal-title":"Lancet"},{"key":"2023052108544622400_ehad119-B30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2016.07.017","article-title":"No benefit from platelet transfusion for gastrointestinal bleeding in patients taking antiplatelet agents","volume":"15","author":"Zakko","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023052108544622400_ehad119-B31","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/blood-2014-10-605493","article-title":"Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality","volume":"125","author":"Goel","year":"2015","journal-title":"Blood"},{"key":"2023052108544622400_ehad119-B32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jama.2021.0135","article-title":"Effect of a restrictive vs liberal blood transfusion strategy on Major cardiovascular events among patients with acute myocardial infarction and anemia: the REALITY randomized clinical trial","volume":"325","author":"Ducrocq","year":"2021","journal-title":"JAMA"},{"key":"2023052108544622400_ehad119-B33","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/j.1538-7836.2006.01986.x","article-title":"Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms","volume":"4","author":"Dentali","year":"2006","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B34","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0049-3848(99)00078-X","article-title":"Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency","volume":"95","author":"Hellstern","year":"1999","journal-title":"Thromb Res"},{"key":"2023052108544622400_ehad119-B35","doi-asserted-by":"crossref","first-page":"j5424","DOI":"10.1136\/bmj.j5424","article-title":"Urgent reversal of vitamin K antagonists","volume":"360","author":"Hunt","year":"2018","journal-title":"BMJ"},{"key":"2023052108544622400_ehad119-B36","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1474-4422(16)00110-1","article-title":"Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial","volume":"15","author":"Steiner","year":"2016","journal-title":"Lancet Neurol"},{"key":"2023052108544622400_ehad119-B37","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1111\/j.1537-2995.2012.03663.x","article-title":"Adverse effects of plasma transfusion","volume":"52","author":"Pandey","year":"2012","journal-title":"Transfusion"},{"key":"2023052108544622400_ehad119-B38","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1161\/CIRCULATIONAHA.111.081489","article-title":"Reversal of warfarin: case-based practice recommendations","volume":"125","author":"Garcia","year":"2012","journal-title":"Circulation"},{"key":"2023052108544622400_ehad119-B39","first-page":"391","article-title":"Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis","volume":"166","author":"Dezee","year":"2006","journal-title":"Arch Intern Med"},{"key":"2023052108544622400_ehad119-B40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1023\/A:1011237019082","article-title":"Anaphylactoid reactions to vitamin K","volume":"11","author":"Fiore","year":"2001","journal-title":"J Thromb Thrombolysis"},{"key":"2023052108544622400_ehad119-B41","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B42","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"2023052108544622400_ehad119-B43"},{"key":"2023052108544622400_ehad119-B44","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B45","first-page":"692","article-title":"Evidence for idarucizumab (praxbind) in the reversal of the direct thrombin inhibitor dabigatran: review following the RE-VERSE AD full cohort analysis","volume":"42","author":"Hutcherson","year":"2017","journal-title":"P T"},{"key":"2023052108544622400_ehad119-B46","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/CIRCULATIONAHA.118.036710","article-title":"Idarucizumab for dabigatran reversal in the management of patients with gastrointestinal bleeding","volume":"139","author":"Van der Wall","year":"2019","journal-title":"Circulation"},{"key":"2023052108544622400_ehad119-B47","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"2023052108544622400_ehad119-B48","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B49","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B50","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/1060028020943160","article-title":"Andexanet alfa, the possible alternative to protamine for reversal of unfractionated heparin","volume":"55","author":"Maneno","year":"2021","journal-title":"Ann Pharmacother"},{"key":"2023052108544622400_ehad119-B51"},{"key":"2023052108544622400_ehad119-B52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2020007116","article-title":"Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants","volume":"137","author":"Ansell","year":"2021","journal-title":"Blood"},{"key":"2023052108544622400_ehad119-B53","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B54","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1160\/TH16-03-0224","article-title":"Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban","volume":"117","author":"Ansell","year":"2017","journal-title":"Thromb Haemost"},{"key":"2023052108544622400_ehad119-B55","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/eurheartj\/ehab637","article-title":"Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects","volume":"43","author":"Ansell","year":"2022","journal-title":"Eur Heart J"},{"key":"2023052108544622400_ehad119-B56","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1182\/bloodadvances.2016003616","article-title":"Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors","volume":"2","author":"Kalathottukaren","year":"2018","journal-title":"Blood Adv"},{"key":"2023052108544622400_ehad119-B57","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jemermed.2019.10.011","article-title":"Current strategies for the management of bleeding associated with direct oral anticoagulants and a review of investigational reversal agents","volume":"58","author":"Kaide","year":"2020","journal-title":"J Emerg Med"},{"key":"2023052108544622400_ehad119-B58","doi-asserted-by":"crossref","first-page":"411","DOI":"10.21037\/atm.2019.07.101","article-title":"Current status of oral anticoagulant reversal strategies: a review","volume":"7","author":"Rawal","year":"2019","journal-title":"Ann Transl Med"},{"key":"2023052108544622400_ehad119-B59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","article-title":"Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis","volume":"3","author":"Piran","year":"2019","journal-title":"Blood Adv"},{"key":"2023052108544622400_ehad119-B60","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"G\u00f3mez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2023052108544622400_ehad119-B61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/anae.12910","article-title":"The current place of tranexamic acid in the management of bleeding","volume":"70","author":"Hunt","year":"2015","journal-title":"Anaesthesia"},{"key":"2023052108544622400_ehad119-B62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.thromres.2014.11.012","article-title":"Tranexamic acid\u2013an old drug still going strong and making a revival","volume":"135","author":"Tengborn","year":"2015","journal-title":"Thromb Res"},{"key":"2023052108544622400_ehad119-B63","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1606424","article-title":"Tranexamic acid in patients undergoing coronary-artery surgery","volume":"376","author":"Myles","year":"2017","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B64","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1056\/NEJMoa2201171","article-title":"Tranexamic acid in patients undergoing noncardiac surgery","volume":"386","author":"Devereaux","year":"2022","journal-title":"N Engl J Med"},{"key":"2023052108544622400_ehad119-B65","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s13054-021-03799-9","article-title":"Effect of tranexamic acid on thrombotic events and seizures in bleeding patients: a systematic review and meta-analysis","volume":"25","author":"Murao","year":"2021","journal-title":"Crit Care"},{"key":"2023052108544622400_ehad119-B66","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jth.13894","article-title":"Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers","volume":"16","author":"Levy","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B67","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1046\/j.1538-7836.2003.00190.x","article-title":"Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP)","volume":"1","author":"Kaufmann","year":"2003","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/jth.13576","article-title":"Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Desborough","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B69","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1097\/CCM.0000000000002057","article-title":"Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the neurocritical care society and the society of critical care medicine","volume":"44","author":"Frontera","year":"2016","journal-title":"Crit Care Med"},{"key":"2023052108544622400_ehad119-B70","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1007\/s12028-020-01055-6","article-title":"Effect of desmopressin on platelet dysfunction during antiplatelet therapy: a systematic review","volume":"34","author":"Andersen","year":"2021","journal-title":"Neurocrit Care"},{"key":"2023052108544622400_ehad119-B71","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the anticoagulation forum","volume":"94","author":"Cuker","year":"2019","journal-title":"Am J Hematol"},{"key":"2023052108544622400_ehad119-B72","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American college of cardiology solution set oversight committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2023052108544622400_ehad119-B73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B74","first-page":"e10290","article-title":"Reversing bleeding associated with antiplatelet use: the role of tranexamic acid","volume":"12","author":"Fischer","year":"2020","journal-title":"Cureus"},{"key":"2023052108544622400_ehad119-B75","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1161\/CIRCULATIONAHA.113.002283","article-title":"Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study","volume":"128","author":"Sarode","year":"2013","journal-title":"Circulation"},{"key":"2023052108544622400_ehad119-B76","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bja.2018.04.025","article-title":"Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab","volume":"121","author":"Hegemann","year":"2018","journal-title":"Br J Anaesth"},{"key":"2023052108544622400_ehad119-B77","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1111\/jth.13117","article-title":"Hemodialysis for the treatment of dabigatran-associated bleeding: a case report and systematic review","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B78","first-page":"1455","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European society of cardiology working group on thrombosis","volume":"38","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J"},{"key":"2023052108544622400_ehad119-B79","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.amjmed.2016.06.003","article-title":"Bleeding with direct oral anticoagulants vs warfarin: clinical experience","volume":"129","author":"Eikelboom","year":"2016","journal-title":"Am J Med"},{"key":"2023052108544622400_ehad119-B80","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1161\/STR.0000000000000407","article-title":"2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American heart association\/American stroke association","volume":"53","author":"Greenberg","year":"2022","journal-title":"Stroke"},{"key":"2023052108544622400_ehad119-B81","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/2396987319849763","article-title":"European Stroke Organisation guideline on reversal of oral anticoagulants in acute intracerebral haemorrhage","volume":"4","author":"Christensen","year":"2019","journal-title":"Eur Stroke J"},{"key":"2023052108544622400_ehad119-B82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13054-019-2347-3","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition","volume":"23","author":"Spahn","year":"2019","journal-title":"Crit Care"},{"key":"2023052108544622400_ehad119-B83","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.0306-5251.2001.01476.x","article-title":"Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies","volume":"52","author":"Garc\u00eda Rodr\u00edguez","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"2023052108544622400_ehad119-B84","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.gastro.2013.02.041","article-title":"New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis","volume":"145","author":"Holster","year":"2013","journal-title":"Gastroenterology"},{"key":"2023052108544622400_ehad119-B85","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","author":"HALT-IT Trial Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2023052108544622400_ehad119-B86","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/a-1369-5274","article-title":"Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): european society of gastrointestinal endoscopy (ESGE) guideline - update 2021","volume":"53","author":"Gralnek","year":"2021","journal-title":"Endoscopy"},{"key":"2023052108544622400_ehad119-B87","first-page":"748","article-title":"The coagulopathy of trauma: a review of mechanisms","volume":"65","author":"Hess","year":"2008","journal-title":"J Trauma"},{"key":"2023052108544622400_ehad119-B88","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jamcollsurg.2018.08.183","article-title":"American College of surgeons\u2019 guidelines for the perioperative management of antithrombotic medication","volume":"227","author":"Hornor","year":"2018","journal-title":"J Am Coll Surg"},{"key":"2023052108544622400_ehad119-B89","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","article-title":"Perioperative management of antithrombotic therapy: an American college of chest physicians clinical practice guideline","volume":"162","author":"Douketis","year":"2022","journal-title":"Chest"},{"key":"2023052108544622400_ehad119-B90","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41569-020-0410-z","article-title":"Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management","volume":"18","author":"Cao","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"2023052108544622400_ehad119-B91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jcin.2017.10.051","article-title":"A multidisciplinary approach on the perioperative antithrombotic management of patients with coronary stents undergoing surgery: surgery after stenting 2","volume":"11","author":"Rossini","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"key":"2023052108544622400_ehad119-B92","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the academic research consortium for high bleeding risk","volume":"40","author":"Urban","year":"2019","journal-title":"Eur Heart J"},{"key":"2023052108544622400_ehad119-B93","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/jth.14598","article-title":"Scientific and standardization committee communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural\/surgical bleed risk and patient-specific thromboembolic risk","volume":"17","author":"Spyropoulos","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B94","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015","journal-title":"Ann Intern Med"},{"key":"2023052108544622400_ehad119-B95","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/VHRM.S44469","article-title":"Platelet function tests: a comparative review","volume":"11","author":"Paniccia","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"2023052108544622400_ehad119-B96","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11239-019-01971-1","article-title":"Comparison of three common whole blood platelet function tests for in vitro P2Y12 induced platelet inhibition","volume":"50","author":"Dias","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2023052108544622400_ehad119-B97","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/j.thromres.2009.11.005","article-title":"The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays","volume":"125","author":"Can","year":"2010","journal-title":"Thromb Res"},{"key":"2023052108544622400_ehad119-B98","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.chest.2016.08.1462","article-title":"Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review","volume":"151","author":"Samuelson","year":"2017","journal-title":"Chest"},{"key":"2023052108544622400_ehad119-B99","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"key":"2023052108544622400_ehad119-B100","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11239-015-1282-7","article-title":"Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication","volume":"41","author":"Cuker","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2023052108544622400_ehad119-B101","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0038-1627480","article-title":"International council for standardization in haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants","volume":"118","author":"Gosselin","year":"2018","journal-title":"Thromb Haemost"},{"key":"2023052108544622400_ehad119-B102","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.16179","article-title":"International external quality assessment for measurements of direct oral anticoagulants: results and recommendations","volume":"188","author":"Hollestelle","year":"2020","journal-title":"Br J Haematol"},{"key":"2023052108544622400_ehad119-B103","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/biomedicines9050445","article-title":"Laboratory monitoring of direct oral anticoagulants (DOACs)","volume":"9","author":"Dunois","year":"2021","journal-title":"Biomedicines"},{"key":"2023052108544622400_ehad119-B104","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ahj.2021.10.188","article-title":"Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: a prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorb\u2122-ATR device in patients undergoing cardiothoracic surgery within 48 h from last ticagrelor dose","volume":"245","author":"Gibson","year":"2021","journal-title":"Am Heart J"},{"key":"2023052108544622400_ehad119-B105","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ehjcvp\/pvac036","article-title":"Antithrombotic drug removal from whole blood using haemoadsorption with a porous polymer bead sorbent","volume":"8","author":"Tripathi","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023052108544622400_ehad119-B106","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2019.06.078","article-title":"Removal of dabigatran using sorbent hemadsorption","volume":"293","author":"Angheloiu","year":"2019","journal-title":"Int J Cardiol"},{"key":"2023052108544622400_ehad119-B107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40268-020-00308-1","article-title":"In-vitro sorbent-mediated removal of edoxaban from human plasma and albumin solution","volume":"20","author":"Angheloiu","year":"2020","journal-title":"Drugs R D"},{"key":"2023052108544622400_ehad119-B108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.athoracsur.2018.12.032","article-title":"Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding","volume":"108","author":"Hassan","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"2023052108544622400_ehad119-B109","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1177\/0267659120967827","article-title":"Cytosorb\u00ae hemoadsorption of apixaban during emergent cardio-pulmonary bypass: a case report","volume":"36","author":"Mendes","year":"2021","journal-title":"Perfusion"},{"key":"2023052108544622400_ehad119-B110","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1182\/blood-2017-05-782060","article-title":"Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study","volume":"130","author":"Majeed","year":"2017","journal-title":"Blood"},{"key":"2023052108544622400_ehad119-B111","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for Major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"2023052108544622400_ehad119-B112","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rth2.12029","article-title":"Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study","volume":"1","author":"Yasaka","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"2023052108544622400_ehad119-B113","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2019000885","article-title":"A phase 2 PK\/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers","volume":"4","author":"Lu","year":"2020","journal-title":"Blood Adv"},{"key":"2023052108544622400_ehad119-B114","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1055\/s-0037-1599153","article-title":"Point-of-care coagulation testing in cardiac surgery","volume":"43","author":"Bolliger","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"2023052108544622400_ehad119-B115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/clc.22472","article-title":"Predicting bleeding risk by platelet function testing in patients undergoing heart surgery","volume":"38","author":"Kuliczkowski","year":"2015","journal-title":"Clin Cardiol"},{"key":"2023052108544622400_ehad119-B116","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/clc.22540","article-title":"Validation of three platelet function tests for bleeding risk stratification during dual antiplatelet therapy following coronary interventions","volume":"39","author":"Kim","year":"2016","journal-title":"Clin Cardiol"},{"key":"2023052108544622400_ehad119-B117","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1080\/09537104.2018.1535706","article-title":"Platelet function after cardiac surgery and its association with severe postoperative bleeding: the PLATFORM study","volume":"30","author":"Ranucci","year":"2019","journal-title":"Platelets"},{"key":"2023052108544622400_ehad119-B118","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3109\/09537104.2016.1173665","article-title":"Early platelet recovery following cardiac surgery with cardiopulmonary bypass","volume":"27","author":"Van Poucke","year":"2016","journal-title":"Platelets"},{"key":"2023052108544622400_ehad119-B119","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1213\/ane.0b013e3181a198ac","article-title":"An assessment of cardiopulmonary bypass-induced changes in platelet function using whole blood and classical light transmission aggregometry: the results of a pilot study","volume":"108","author":"Velik-Salchner","year":"2009","journal-title":"Anesth Analg"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/20\/1780\/50389867\/ehad119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/20\/1780\/50389867\/ehad119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T08:55:52Z","timestamp":1684659352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/20\/1780\/7093050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":119,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2023,3,29]]},"published-print":{"date-parts":[[2023,5,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad119","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,21]]},"published":{"date-parts":[[2023,3,29]]}}}